Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ELIAS Animal Health
Olathe, Kansas, United Stateseliasanimalhealth.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
ECI® became the first USDA-approved adoptive cell therapy for canine osteosarcoma in 2025, demonstrating improved quality of life and potential survival benefits over standard chemotherapy. More than 300 canine patients have been treated in studies and early access programs. The platform is expanding to other cancer types and includes an oncolytic virotherapy (ELI352) in preclinical research.
- Therapeutic areas
- Oncology
- Modalities
- VaccineCell therapyOncolytic virus therapy
- Industry
- Veterinary
Beyond the preview
Go deeper on ELIAS Animal Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELIAS Animal Health.